-
Get the latest information and research on osteoporosis.
-
Find treatment, guidance and advice on living with osteoporosis.
-
Share your experience and get involved. Joining the conversation is the first step to ending osteoporosis and broken bones.
NOF
May 10, 2012
In response to the Perspectives pieces published online today by the New England Journal of Medicine, the National Osteoporosis Foundation (NOF) commends the U.S. Food and Drug Administration (FDA) for its continued analysis of long-term bisphosphonate treatment in order to help patients and healthcare providers determine the appropriate length of time for treatment and urges patients not to stop treatment without first talking with their healthcare provider.
NOF
April 28, 2012
The National Osteoporosis Foundation (NOF) named five new members to its Board of Trustees during the International Symposium on Osteoporosis, its annual meeting yesterday. NOF is proud to welcome Franmarie Kennedy; Joan M. Lappe PhD, RN, FAAN; C. Berdon Lawrence; Meryl S. LeBoff, M.D.; and C. Michael Lewiecki, M.D., FACP, FACE, FACP as new trustees.
NOF
April 28, 2012
The nation’s top osteoporosis researchers and clinicians will gather in Orlando, Florida this week for the National Osteoporosis Foundation’s (NOF) International Symposium on Osteoporosis (ISO12): Translating Research into Clinical Practice. Held annually, the meeting is the premier scientific event entirely dedicated to the treatment and study of osteoporosis and aims to close the gap between osteoporosis research and its application in clinical practice. As the 2012 recipient of the Lawrence G.
NOF
April 26, 2012
NOF and CMH Summer Adventures invite women across California to attend Using Travel to Jump Start Change: A Conversation with Marybeth Bond. Don’t miss this opportunity to hear directly from Generations of Strength National Honorary Committee member and best-selling author, Marybeth Bond about “what makes life meaningful" and simple ways to contribute to a cause greater than yourself. This women-only event will take place at The General’s Residence, Fort Mason Center, San Francisco, on Tuesday, May 1.
NOF
April 5, 2012
The National Osteoporosis Foundation (NOF) agrees with the recommendation released today as part of the Choosing Wisely campaign that women under age 65 and men under age 70 should not be screened for osteoporosis with dual energy X-ray absorptiometry (DXA). But the nations leading community health organization dedicated to preventing osteoporosis and broken bones cautions patients to consult with their physicians about their risk factors before deciding to forgo the test.
NOF
April 5, 2012
DXA Not Necessary for Women Under Age 65 and Men Under Age 70 with No Osteoporosis Risk Factors, but Remains Widely Underutilized among those with Highest Fracture Risk.
NOF
Washington, DC
April 4, 2012
DXA Not Necessary for Women Under Age 65 and Men Under Age 70 with No Osteoporosis Risk Factors, but Remains Widely Underutilized among those with Highest Fracture Risk
FDA
March 22, 2012
The U.S. Food and Drug Administration (FDA) has approved the first generic versions of Boniva® (ibandronate), a once-monthly prescription tablet used for the prevention and treatment of osteoporosis in women after menopause. Ibandronate is in a class of drugs called bisphosphonates that help increase bone mass and reduce the chance of broken bones.
NOF
February 24, 2012
Congress did not include an extension of the current Medicare reimbursement rates for DXA in the Middle Class Tax Relief and Job Creation Act, H.R. 3630. Despite a strong advocacy effort carried out by NOF and the DXA Coalition in contacting Members of Congress, as well as strong bipartisan support among many of the House and Senate conferees who negotiated the tax package, there was some opposition to extending the current Medicare reimbursement rates for DXA, resulting in the provisions being eliminated from the final package.
NOF
January 24, 2012
NOF Responds to Media Coverage of the New England Journal of Medicine study “Bone-Density Testing Interval and Transition to Osteoporosis in Older Women” and Encourages Current Patients to Continue Working with their Healthcare Providers to Regularly Monitor their Condition
